News Center
Livzon Group's Semaglutide Injection has completed the enrollment of all cases in the Phase III clinical trial for weight management indications.
Release time:
2024-12-04
Good news has come from research and innovation. Recently, the clinical trial for the weight management indication of the semaglutide injection developed by New Beijiang Pharmaceutical Co., Ltd., a subsidiary of Livzon Group, has completed the enrollment of all cases in Phase III clinical trials. The rapid progress of the clinical trial has laid a solid foundation for the drug's market launch.
The semaglutide injection is a biosimilar drug independently developed by Livzon Group. The indication for this clinical trial is chronic weight management for adult patients with an initial body mass index of 30 kg/m² or above (obesity) or 27 kg/m² or above (overweight) and at least one weight-related comorbidity (such as hypertension, dyslipidemia, fatty liver, obstructive sleep apnea syndrome).
The semaglutide injection obtained the clinical approval for the weight management indication in February 2024 and initiated clinical trials. As a long-acting GLP-1 receptor agonist, semaglutide injection has effects such as lowering blood sugar, protecting cardiovascular health, and controlling weight. Driven by application demand, its market share continues to increase. According to the original research by Novo Nordisk, the global sales of semaglutide injection and oral tablets in the first three quarters of this year reached $20.59 billion, indicating huge market potential.
As an innovative pharmaceutical company, Livzon Group actively responds to industry and market challenges, deeply focusing on unmet clinical needs. Driven by independent research and development and business development, it continuously increases the innovation efforts for high-barrier complex formulations, with several key projects under research achieving phased results. In the future, Livzon Group's innovative achievements will be gradually realized, benefiting more patients.
Related Information